Revenue Growth - Revenue increased from $699.6 million to $1.1 billion from the fiscal year ended January 31, 2024, to the fiscal year ended January 31, 2026, indicating significant growth[111] - The company increased its employee count from 2,379 on January 31, 2024, to 3,229 by January 31, 2026, and expanded its customer base from over 2,760 to approximately 3,235 during the same period[139] - Customer growth was notable, rising from over 2,760 to approximately 3,235 between January 31, 2024, and January 31, 2026[139] Customer Acquisition and Retention - Customer retention is critical, as customers typically enter into three-year contracts with annual billing upfront, and there is no obligation to renew[114] - The company emphasizes the importance of acquiring new customers and expanding sales to existing customers to sustain growth[113] - The company faces risks in acquiring new customers and retaining existing ones, which could adversely affect revenue growth[113] Market Dynamics - The market for identity security solutions is rapidly evolving, and the company's future success depends on the growth of this market[120] - Significant competition exists from larger established companies and emerging technologies, which may impact the company's market position[134] - Competitive pressures from new technologies, particularly those leveraging AI, could lead to reduced revenue and market share if not effectively addressed[138] Sales Cycle and Revenue Recognition - The sales cycle is long and unpredictable, requiring significant time and resources to educate potential customers[126] - Revenue recognition is primarily ratable over the term of agreements, which may delay the reflection of downturns or upturns in sales[130] - The company’s sales cycles for enterprise customers are longer and more complex, which may result in unpredictability in revenue recognition[149] Operational Complexity and Investment - The company anticipates continued complexity in operations as it grows, necessitating substantial investments in operational, financial, and management controls[139] - The company expects continued seasonality to impact sales and remaining performance obligations (RPO), particularly as it targets larger enterprise customers[141] - The growth in customer base will require expansion of professional services and enhancement of the partner network to maintain high customer service levels[140] Risks and Challenges - The company faces risks associated with international operations, including competition, cultural differences, and political instability, which could impact financial results[152] - Macroeconomic uncertainties, including inflation and geopolitical conflicts, may negatively affect customer spending on technology and identity security solutions[154] - The company is at risk of state-sponsored cyber attacks due to geopolitical conflicts, which could impact business operations and product development[157] Compliance and Regulatory Issues - The company is subject to increased legal and compliance costs due to reporting requirements, which could strain resources and impact financial performance[143] - The company is subject to various privacy and data protection laws, including the California Consumer Privacy Act, which imposes civil penalties of up to $7,998 per violation, increasing compliance costs and risks[234] - Non-compliance with privacy laws, such as GDPR, could result in fines of up to EUR 20 million or 4% of global revenue, creating significant liability and reputational risks[235] Technology and Security - Cybersecurity breaches could disrupt operations and expose the company to liability, particularly as it becomes a more attractive target for cyber attacks[188] - The effectiveness of the company's security measures could be harmed by actual or perceived breaches, leading to potential loss of sales and increased regulatory scrutiny[192] - The integration of AI into the company's solutions may present business, compliance, and reputational challenges, potentially leading to operational damage and additional costs[181] Financial Position and Capital Structure - The company is currently party to a five-year $250.0 million senior secured revolving credit facility, with no outstanding borrowings or letters of credit under the agreement[226] - The company may need to raise additional capital, which could lead to dilution of ownership interests or unfavorable financing terms[164] - The company may incur significant indebtedness, which could reduce strategic flexibility and liquidity[226]

Drug Development and Clinical Trials - Relmada Therapeutics terminated the esmethadone program effective July 7, 2025, following a setback in 2024 [20]. - The company in-licensed NDV-01, a novel controlled-release formulation for NMIBC, on March 24, 2025, with a $3.5 million upfront payment and 3,017,420 shares issued [52]. - NDV-01 is currently in a Phase 2 clinical trial in Israel, with plans to initiate Phase 3 trials for high-risk, BCG-unresponsive NMIBC and intermediate-risk patients in mid-2026 [21][24]. - Sepranolone, acquired from Asarina Pharma for €3 million, is being developed for conditions like Prader-Willi syndrome and Tourette syndrome, with a Phase 2b study expected to start in mid-2026 [50][42]. - Twelve-month safety data for NDV-01 showed no Grade ≥3 treatment-related adverse events among 48 patients, with 63% experiencing treatment-related adverse events [29]. - The complete response rate for NDV-01 at 12 months was 76% among efficacy evaluable patients, with a 94% response rate in the BCG-unresponsive subpopulation [30]. - Key upcoming milestones include FDA IND clearance for NDV-01 and initiation of Phase 2b study for sepranolone, both expected in mid-2026 [24][42]. - The NDV-01 formulation allows for sustained localized chemotherapy delivery for up to 10 days, improving patient convenience compared to conventional methods [26][27]. - The company terminated the development of its former primary drug candidate, esmethadone, due to an interim analysis indicating futility in its Phase 3 study, resulting in a loss of significant time, resources, and capital [110]. - The company is now focusing on two new drug candidates, NDV-01 and sepranolone, which are in early stages of development, with limited data on their safety, efficacy, or commercial viability [111]. - Regulatory approval for drug candidates is subject to rigorous clinical trials and extensive processes, with a high failure rate for drugs in development [114]. - Delays in clinical trials can arise from various factors, including patient recruitment challenges and regulatory approvals, affecting revenue generation [156]. Financial Performance and Funding - Relmada reported a net loss of approximately $57.4 million for the year ended December 31, 2025, with an accumulated deficit of approximately $698.3 million [45]. - The company may require substantial additional funding to support ongoing research and operational expenses, with no guarantee of securing funding on favorable terms [118]. - The company has cash, cash equivalents, and short-term investments of approximately $93.0 million as of December 31, 2025 [122]. - The company has Federal and State net operating loss (NOL) carryforwards of approximately $246.4 million and $2.7 million, respectively, which begin expiring in 2027 and 2032 [125]. - The company expects to continue to operate at a net loss for at least the next several years due to ongoing research and development efforts [120]. - The company has incurred substantial losses since inception, with an accumulated deficit of approximately $698.3 million as of December 31, 2025 [122]. Regulatory Environment and Compliance - The FDA review process for NDAs typically takes 10 to 12 months, with priority review available for drugs offering major advances [66]. - The cost of preparing and submitting an NDA is substantial, including application user fees that increase annually [65]. - Orphan Drug Designation provides a seven-year exclusive marketing period for the first NDA applicant to receive approval for a specific indication [74]. - The company is required to register and disclose clinical trial information, which may be used by competitors to gain insights into development programs [75]. - The Inflation Reduction Act (IRA) requires HHS to negotiate the selling price of a specified number of drugs and biologics each year, with the first negotiated prices effective in 2026 [93]. - The IRA imposes rebates on Medicare Part D and Part B drugs whose prices increase faster than inflation, with finalized regulations for these rebates announced in November 2024 [93]. - The company faces significant expenses and limitations in commercializing drugs due to ongoing FDA obligations and regulatory reviews [144]. - Compliance with various federal and state healthcare laws is essential, as violations can lead to significant penalties and legal risks [92]. - The company may face delays in obtaining regulatory approvals, which could diminish competitive advantages and adversely affect operating results [134]. Intellectual Property and Market Position - The company has over 40 patents related to sepranolone and more than 10 patents related to NDV-01, potentially providing market exclusivity beyond 2038 [47][48]. - The company's patent position is highly uncertain, with potential challenges in obtaining and enforcing patents, which could materially harm its business [167]. - There is a risk that the company's owned and licensed patents may not be valid, impacting its ability to conduct business effectively [168]. - The company relies on unpatented trade secrets and confidential know-how for its scientific and commercial success, but these may not be adequately protected [169]. - The company intends to rely on Hatch-Waxman exclusivity for commercialization in the U.S., but may not meet the requirements for 5-year exclusivity [151]. - European data exclusivity may not protect against competition, as competitors could submit marketing applications with less comprehensive data [152]. Operational Challenges and Risks - The company faces significant uncertainty regarding insurance coverage and reimbursement for its products, as third-party payors are increasingly reducing reimbursements [97]. - The company faces intense competition from larger pharmaceutical companies and may struggle to compete effectively due to limited resources [162]. - The company relies on third-party manufacturers for drug production, and any failure by these manufacturers to meet regulatory requirements could materially harm product development and commercialization efforts [199]. - The company intends to rely on third parties for conducting non-clinical studies and clinical trials, which may lead to less control over the timing and quality of these studies [203]. - Supply disruptions from active pharmaceutical ingredient (API) suppliers could significantly delay development and commercialization [154]. - The company may need to shift focus to new therapeutic areas due to failures in drug development or unfavorable market conditions [153]. Human Capital and Corporate Governance - As of December 31, 2025, the company had a total of 17 employees, emphasizing the importance of human capital for innovation and operational excellence [98]. - The company maintains a competitive compensation and benefits package, with performance-based compensation designed to reward contributions to success [99]. - The company currently has only 17 full-time employees and plans to hire additional qualified personnel to support its operations [127]. - The company may face challenges in developing and implementing internal controls required by the Sarbanes-Oxley Act, potentially impacting its ability to report financial results accurately [212]. Market and Stock Performance - The company received a deficiency letter from Nasdaq on January 21, 2025, indicating it did not meet the minimum $1.00 per share bid price requirement for continued inclusion [208]. - On September 15, 2025, the company regained compliance with Nasdaq Listing Rules after the closing bid price of its common stock was at $1.00 per share or greater for 10 consecutive trading days [208]. - The market price of the company's common stock is likely to be highly volatile, influenced by various factors beyond its control [214]. - The termination of development of former drug candidates and the shift to new development programs may contribute to significant volatility in the stock price [215]. Cybersecurity and Data Privacy - Cybersecurity incidents could lead to significant financial and reputational harm, as well as disruptions in development programs [177]. - Compliance with existing and future data privacy and security laws is critical, as failure to comply could lead to significant penalties and negatively affect operating results [179]. - The evolving regulatory landscape regarding data processing may increase operational costs and limit competitiveness [178].

Financial Performance - The company incurred net losses of £29.4 million for the year ended December 31, 2025, and has an accumulated deficit of £252.3 million as of the same date[45]. - The company has an accumulated deficit totaling £252.3 million and cash flows used in operating activities of £7.5 million for the year ended December 31, 2025[68]. - As of December 31, 2025, the company had £24.3 million in cash and cash equivalents, which is expected to fund operations for at least the next twelve months[64]. - The company anticipates substantial additional funding will be required to complete the development and commercialization of its product candidates[63]. - The company may need to raise additional funds if it chooses to pursue additional indications or geographies for its product candidates[68]. Product Development and Clinical Trials - Product candidate NUC-7738 is currently in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors, while NUC-3373 is being evaluated in a Phase 1b/2 modular clinical trial[45]. - The company has invested substantially in the development of NUC-7738 and NUC-3373, with no revenues expected for at least the next several years[51]. - The company is conducting a Phase 1/2 clinical trial (NuTide:701) evaluating NUC-7738, with a focus on advanced solid tumors and PD-1 inhibitor-resistant melanoma[109]. - The company is also running a Phase 1b/2 modular clinical trial (NuTide:303) for NUC-3373 in combination with pembrolizumab and docetaxel for advanced solid tumors and lung cancer, respectively[109]. - Clinical trials may face delays due to difficulties in patient enrollment and site initiation, impacting overall development timelines[92]. Regulatory Challenges - The company plans to seek regulatory approval for NUC-7738 and NUC-3373 in the United States and the European Union, facing varying regulatory requirements across jurisdictions[57]. - The company has not submitted any New Drug Applications (NDA) or Marketing Authorization Applications (MAA) for its product candidates and does not expect to do so in the foreseeable future[56]. - The company may face significant delays or inability to commercialize NUC-7738 and NUC-3373 if it does not overcome regulatory and clinical trial challenges[55]. - Regulatory approval processes may be delayed due to disagreements with the FDA regarding clinical trial designs and data interpretations, as highlighted by the FDA's 2022 guidance on "Project Optimus"[112]. - The company faces challenges in obtaining marketing approvals in foreign markets due to varying regulatory requirements and potential delays in the approval process[169]. Competition and Market Risks - The company faces substantial competition, which may impact the commercialization of its product candidates[43]. - The company anticipates that competition from major pharmaceutical and biotechnology companies will be substantial, particularly in the cancer treatment market[210]. - The potential for significant competition exists, particularly for the company's product candidates NUC-7738 and NUC-3373, which would compete with existing therapies and generics[211]. - The company faces significant competition from larger firms with greater financial resources and expertise in R&D, manufacturing, and marketing, which may hinder its market entry and position[215]. Operational and Compliance Risks - The company must establish a robust supply chain and seek marketing approvals for its product candidates that successfully complete pivotal clinical trials[52]. - The company relies on third-party contract manufacturers for the production and shipment of its product candidates, increasing risks related to supply and quality control[191]. - Compliance with anti-corruption laws, such as the U.K. Bribery Act and the U.S. FCPA, is essential, as violations could lead to significant penalties and impact the company's financial condition[179]. - Environmental, health, and safety regulations impose additional compliance costs, and failure to adhere could result in substantial fines and operational impairments[180]. - The company is subject to stringent data privacy regulations, including GDPR and U.K. GDPR, which impose compliance burdens and potential liabilities related to personal data handling[117]. Financial and Market Conditions - Inflation and tariffs may increase the company's overall cost structure, adversely affecting liquidity and financial condition[82]. - Unstable market conditions have led to extreme volatility in financial markets, potentially making capital raising more difficult and costly[96]. - Future government shutdowns could impact the company's access to public markets and necessary capital, affecting operational continuity[72]. - Changes in the tax system could materially affect the company's financial condition and results of operations, increasing estimated tax liabilities[80]. Intellectual Property and Legal Risks - The company must maintain adequate intellectual property protection to prevent competitors from commercializing similar technologies, which is crucial for successful product commercialization[229]. - The patent portfolio includes both patents and applications, which are essential for protecting proprietary technology and products[230]. - Cybersecurity incidents pose risks to the company's data integrity and could disrupt product development programs, leading to potential legal and financial repercussions[222]. - The company may face increased litigation against regulatory agencies due to recent U.S. Supreme Court decisions, creating uncertainty in regulatory compliance[74]. Marketing and Sales Challenges - The company currently lacks a marketing capability or sales force, which may impede its ability to effectively sell or market approved product candidates[220]. - Establishing a sales and marketing team is costly and time-consuming, and any delays in commercialization could result in lost investments[220]. - Coverage and reimbursement decisions for new medicines in the U.S. are primarily made by CMS, with private payors often following CMS guidelines, making reimbursement uncertain[217]. - Delays in obtaining reimbursement for newly approved drugs may limit coverage and impact the company's ability to recover costs associated with research and development[218].

Financial Performance - The company reported net losses of $243.3 million and $294.2 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $901.9 million as of December 31, 2025[195]. - The company has U.S. federal net operating loss carryforwards of $281.2 million and state net operating loss carryforwards of $5.9 million as of December 31, 2025[304]. - The company currently generates no revenue and may never be able to develop or commercialize any products[258]. - The company’s future net losses will depend on the growth rate of expenses and its ability to generate revenue or raise additional capital[197]. Clinical Development - The company is conducting a Phase 2 open-label extension trial and a Phase 3 LTE trial for its most advanced candidate, envu, which is an oral small molecule allosteric inhibitor of TYK2[194]. - The company discontinued its Phase 2a clinical trial of envu in patients with non-infectious uveitis in June 2024 due to efficacy results not meeting clinical success thresholds[198]. - The company has initiated a Phase 2b trial of envu in SLE, but issues may arise that could delay development timelines[264]. - The company is focusing its development efforts on two main product candidates: envu for PsO and SLE, and A-005 for neuroinflammatory and neurodegenerative diseases[279]. Regulatory Environment - The FDA's new Clinical Trials Regulation (CTR) became applicable on January 31, 2022, streamlining the submission process for clinical trials in the EU[218]. - The UK government has enacted new legislation to overhaul the clinical trials regulatory framework, with changes effective from April 28, 2026[219]. - The regulatory approval processes are lengthy and unpredictable, which could substantially harm the company's business if approvals are not obtained[263]. - Regulatory approval processes in other countries may involve additional testing and administrative review periods, which could delay market entry[238]. Financial Strategy - The company has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to raise up to $300.0 million through the sale of common stock[205]. - The company will require substantial additional financing to continue product development and may face delays or limitations if funding is not secured[205]. - Future acquisitions may require additional financing, which may not be available on favorable terms[301]. - The company anticipates significant increases in expenses related to preclinical studies and clinical trials for envu and A-005, as well as costs associated with regulatory approvals and commercialization efforts[196]. Market Challenges - The company faces significant competition from established therapies and must demonstrate meaningful improvements to achieve market penetration[249]. - Third-party payors are increasingly challenging prices for biopharmaceutical products, which may limit coverage and reimbursement for the company's product candidates[240]. - The company anticipates pricing pressures due to governmental and third-party efforts to cap healthcare costs, which may affect revenue opportunities[248]. - Public perception of immunology treatments may adversely affect the company’s ability to conduct business and enroll clinical trials[333]. Intellectual Property Risks - The company’s ability to maintain sufficient intellectual property protection is critical, as failure to do so could allow competitors to develop similar products[337]. - The company may face challenges in obtaining and enforcing patents, which are essential for protecting its competitive position in the market[339]. - The uncertainty surrounding patent rights and potential litigation could affect the commercial value of the company’s intellectual property[343]. - The company may face expensive and time-consuming lawsuits to protect its patents and intellectual property, which could adversely affect its competitive position and financial condition[366]. Operational Risks - The company relies on third parties for manufacturing its product candidates, with most suppliers located outside the United States, particularly in India and Taiwan[290]. - The U.S. government imposed a 10% global tariff in April 2025, which may increase research and development expenses and complicate the supply chain[289]. - The company faces significant product liability risks during clinical trials, which could lead to delays, increased costs, and negative impacts on reputation and stock price[296]. - The company’s operations are predominantly located in California, making it vulnerable to natural disasters that could materially affect business continuity and financial conditions[324]. Cybersecurity Concerns - The company faces evolving cybersecurity threats that could disrupt operations and compromise sensitive information[310]. - Significant security breaches could result in material costs and expenses for the company[319]. - The company relies on third-party service providers, which introduces additional cybersecurity risks and vulnerabilities[317]. - Security incidents could lead to significant delays in regulatory approval efforts and increase costs to recover lost data[320].

Store Operations and Expansion - As of January 31, 2026, Ollie's operated 645 retail stores across 34 states, with plans to expand to over 1,300 locations nationally[18][34]. - The company opened 86 new stores in fiscal 2025, increasing the total from 559 to 645 stores[35]. - The company has a robust pipeline for new store locations, focusing on low-cost, second-generation sites to optimize returns on invested capital[34]. - The company’s growth strategy includes opening new stores, but challenges such as lease negotiations and market conditions could hinder timely expansion[88]. - New store openings in different geographic markets may face unique challenges, including higher entry costs and varying customer demographics, potentially affecting overall performance[89]. Financial Performance - Net sales increased to $2.649 billion in 2025 from $2.272 billion in 2024, an increase of $377 million, or 16.6%[195]. - Comparable store sales increased by 3.7% in 2025 compared to a 2.8% increase in 2024, driven by an increase in the number of transactions and basket size[195]. - Gross profit rose to $1.073 billion in 2025 from $914.5 million in 2024, an increase of $158.5 million, or 17.3%, with gross margin increasing to 40.5%[196]. - Selling, general, and administrative expenses increased to $709 million in 2025 from $612.4 million in 2024, an increase of $96.6 million, or 15.8%[197]. - Net income increased to $240.6 million in 2025 from $199.8 million in 2024, an increase of $40.8 million, or 20.4%[202]. - Adjusted EBITDA increased to $366 million in 2025 from $313.1 million in 2024, an increase of $52.9 million, or 16.9%[203]. Operational Efficiency - The company maintains a low-cost operational structure, focusing on expense control and efficient distribution, with four distribution centers totaling approximately three million square feet[28][42]. - Ollie's distribution network is designed to minimize logistics costs and optimize shipping efficiencies, with plans to expand existing distribution centers in 2026 and 2027[42]. - The company relies on centralized distribution centers in York, PA, Commerce, GA, Lancaster, TX, and Princeton, IL, for inventory processing and shipping, which is critical for operational efficiency[90]. - Efficient inventory management is crucial for profitability; failure to align inventory levels with customer demand could lead to unanticipated markdowns[92]. Marketing and Customer Engagement - Ollie's Army loyalty program had approximately 17 million members as of January 31, 2026, contributing to over 80% of net sales and members spending about 40% more per transaction than non-members[39]. - Ollie's marketing strategy emphasizes the "treasure hunt" shopping experience, utilizing digital marketing, print advertising, and community engagement to drive store traffic[40][41]. - Marketing and promotional efforts are vital for attracting customers; over 40% of advertising spend in 2025 was allocated to printed flyers[98]. Supply Chain and Risks - The company faces risks related to supply chain disruptions, which could adversely affect inventory management and sales[61]. - The company does not have long-term contracts with suppliers, which may impact pricing and availability of merchandise[68]. - The company depends on third-party transportation for merchandise delivery, and disruptions in shipping or increased transportation costs could adversely affect operations[71]. - Rising costs due to inflation, tariffs, and energy prices may reduce profitability, as the company’s pricing model may not accommodate these increases[72]. - The majority of the company's private label inventory purchases during fiscal 2025 were imports, indicating a reliance on international suppliers[104]. Human Resources and Labor - As of January 31, 2026, the company employed over 13,000 associates, with more than half being full-time[49]. - Over 65% of current district team leaders were internally promoted, reflecting the company's commitment to internal talent development[53]. - The company provides market-competitive compensation and various bonus incentive programs based on store and company performance[54]. - Labor shortages and increased turnover rates have led to higher operational costs, impacting the company's ability to operate efficiently[94]. - The company faces intense competition for skilled personnel, which is essential for maintaining operational effectiveness and customer service quality[96]. Compliance and Legal Risks - The company is subject to various state and federal laws, including labor and employment laws, which it believes it complies with materially[46]. - The company monitors changes in laws and regulations that could materially affect its business operations and financial condition[46]. - Compliance with product safety regulations may lead to product recalls, potentially resulting in lost sales and increased costs, adversely affecting financial results[105]. - Litigation risks from various stakeholders could result in significant costs and negatively affect operating results, with potential for large or indeterminate claims[107]. Financial Position and Capital Management - The company had $296.3 million in cash and cash equivalents as of January 31, 2026, with $86.5 million available to borrow under its Revolving Credit Facility[204]. - The company does not expect to pay any cash dividends for the foreseeable future, as continued operation and expansion will require substantial funding[128]. - The company's credit facility includes a $45.0 million sub-facility for letters of credit and a $25.0 million sub-facility for swingline loans[135]. - The company may incur substantial additional indebtedness under its credit facility, which could limit its operational flexibility[136]. - The company's share repurchase program may not enhance long-term stockholder value and is subject to fluctuations based on cash flow and market conditions[141]. Cybersecurity and Technology - The company maintains a comprehensive cybersecurity program, regularly assessing and testing its policies and practices[144]. - The company has established an Artificial Intelligence policy to support the responsible use of AI technologies while managing associated risks[147]. - The company has not experienced any material impact from previously identified cyberattacks during the fiscal year ended January 31, 2026[153]. - Disruptions to information technology systems or breaches of network security could have a material adverse effect on business operations and financial condition[109]. - Increasing data protection requirements may raise operating costs and expose the company to regulatory risks and potential fines for non-compliance[113].

Financial Performance - Q4 2025 total revenue was $22.2 million, in line with guidance, while Adjusted EBITDA was $2.5 million, exceeding guidance [3]. - Total revenues for the full year 2025 were $95.4 million, a decrease of 21% compared to 2024 [14]. - FiscalNote's Adjusted EBITDA for the full year 2025 was $10.3 million, a 5% increase from the previous year [14]. - Total revenues for the year ended December 31, 2025, were $95.407 million, down from $120.266 million in 2024 [31]. - The company reported an operating loss of $49.504 million for the year ended December 31, 2025, compared to a loss of $31.941 million in 2024 [31]. - The net loss for the year ended December 31, 2025, was $65.247 million, compared to a net income of $9.517 million in 2024 [31]. - For the three months ended December 31, 2025, the company reported a net loss of $22,871,000 compared to a net loss of $13,383,000 for the same period in 2024 [45]. - The company reported a total loss of $65,247,000 for the twelve months ended December 31, 2025, compared to a profit of $9,517,000 in 2024 [45]. Revenue Trends - Subscription revenue for Q4 2025 declined by $5.9 million, or 22%, primarily due to divestitures of several businesses [10]. - Annual Recurring Revenue (ARR) as of December 31, 2025, was $84.1 million, representing a 21% decline year-over-year [11]. - Subscription revenues for the year ended December 31, 2025, were $88.982 million, a decrease from $111.073 million in 2024 [31]. - The company’s total Annual Recurring Revenue (ARR) is primarily subscription-based, contributing to over 90% of total revenues, indicating high revenue predictability [50]. Cost Management and Strategic Initiatives - FiscalNote plans a workforce reduction of approximately 25% to drive organizational transformation and anticipates positive Free Cash Flow by the end of Q1 2027 [4]. - The company anticipates achieving positive Free Cash Flow on a trailing 12-month basis by the end of Q1 2027, following cost reduction initiatives and disciplined financial execution [17]. - The company plans to drive significant reductions in its cost base through AI tools and operational discipline, aiming for expanded Adjusted EBITDA margins year over year [17]. - The company is undergoing a strategic review to evaluate potential divestitures of non-core assets, with no set timetable for completion [18]. Future Projections - The financial guidance for 2026 anticipates total revenues between $80 million and $83 million, with Adjusted EBITDA projected between $14 million and $16 million [16]. - Total revenues for Q1 2026 are projected to be between $20 million and $21 million, compared to $23.1 million in Q1 2025 [17]. - Adjusted EBITDA for Q1 2026 is expected to be approximately $1 million, down from $1.6 million in Q1 2025 [17]. Asset and Cash Flow Analysis - Total assets decreased from $326,197 million in 2024 to $255,138 million in 2025, a decline of approximately 21.8% [33]. - Cash and cash equivalents decreased from $28,814 million in 2024 to $24,319 million in 2025, a reduction of approximately 15.5% [33]. - Net cash used in operating activities was $11,443 million in 2025, compared to $5,298 million in 2024, reflecting a worsening cash flow situation [35]. - Capital expenditures decreased from $8,884 million in 2024 to $7,203 million in 2025, a decline of approximately 18.9% [35]. Operational Metrics - New corporate logo bookings increased by 39% year-over-year, and the share of multi-year contracts among private sector customers rose from 17% to 40% [3]. - Adjusted Gross Profit Margin improved slightly to 88% in Q4 2025 from 87% in Q4 2024 [44]. - Depreciation and amortization expenses for the twelve months ended December 31, 2025, were $17,974,000, slightly down from $19,869,000 in 2024 [45]. - Interest expense for the twelve months ended December 31, 2025, was $16,488,000, compared to $23,589,000 in 2024, indicating a reduction in financing costs [45]. Market Expansion and Innovation - The company is expanding its PolicyNote API and introducing Model Context Protocol (MCP) support to enhance its offerings in AI-driven policy analysis [5]. - FiscalNote is entering the political prediction market, leveraging proprietary datasets to create new monetization opportunities [5]. - The company’s strategic focus includes ongoing evaluation of key performance indicators to inform growth trends and operational performance [49]. - Net Revenue Retention (NRR) is calculated by comparing recognized recurring revenue from existing customers, reflecting the company's success in retaining and growing revenue [51].

Financial Performance - Revenues for the year ended December 31, 2025 increased by $2,669 or 13% to $22,666 compared to $19,997 for the year ended December 31, 2024, primarily driven by higher SaaS revenue [146]. - Gross profit increased by $2,334 or 13% to $20,500 for the year ended December 31, 2025, with a gross profit margin of 90.4% [147]. - Net income for the year ended December 31, 2025 was $1,273, or $0.07 per share, compared to a net loss of $(918), or $(0.05) per share, for the year ended December 31, 2024 [151]. - Adjusted Gross Profit for the year ended December 31, 2025 was $20,999, representing 92.6% of revenues [159]. - Adjusted EBITDA for 2025 was $2,566 million, compared to $520 million in 2024, indicating a substantial increase in operational performance [163]. - For the year ended December 31, 2025, the company reported a net income of $1,273 million, a significant improvement from a net loss of $918 million in 2024 [163]. Operating Expenses - Operating expenses increased by $80 or 0.4% to $19,414 for the year ended December 31, 2025, with research and development expenses rising by $1,457 or 38% [148]. - The company has approximately $682 million in research and development credits available [164]. Cash Flow and Liquidity - Cash provided by operating activities was $4,541 for the year ended December 31, 2025, compared to cash used in operating activities of $(2,694) for the year ended December 31, 2024 [153]. - As of December 31, 2025, the company had cash and cash equivalents of $9,650 and working capital of $10,123 [152]. - The company anticipates that available cash and expected cash from operations will be sufficient to meet anticipated working capital and capital expenditure requirements for at least the next 12 months [154]. - As of December 31, 2025, the company held cash and cash equivalents of $9,650 million, with no material impact expected from a hypothetical 100 basis point change in interest rates [172]. Tax and Valuation - The company maintained a full valuation allowance of approximately $6,677 against its net deferred tax assets as of December 31, 2025 [143]. - The company has approximately $30,520 million in net operating loss carryforwards, with $10,892 million expiring between 2035 and 2037 [164]. Regulatory and Accounting Changes - The company adopted ASU 2023-09 effective January 1, 2025, which did not have a material impact on its consolidated financial statements [165]. - The company is evaluating the impact of ASU 2024-03, effective after December 15, 2026, which requires disaggregated disclosures for certain expenses [167]. - The company plans to adopt ASU 2025-05 in Q1 2026, which addresses credit loss measurement for accounts receivable and is not expected to materially impact financial statements [168]. Strategic Initiatives - The company filed an S-3 registration in August 2025 to allow for potential future fundraising to support business expansion and other strategic initiatives [155]. - The company expects to continue focusing on capital preservation and liquidity needs in its investment activities [172]. Financing Arrangements - The company has never engaged in off-balance sheet financing arrangements or established special purpose entities [171].

Financial Performance - Revenue for the full year 2025 increased by $133 million, or 52%, to $386 million, primarily driven by increased completion against two Transport Layer Tranche 2 contracts[3] - Gross profit grew 133% to $75 million, with gross margin increasing by 6.8 percentage points to 19.5% due to reduced negative EAC adjustments and improved program mix[4] - Net loss decreased by 15% to $(84,537) thousand compared to $(98,911) thousand in 2024[2] - Adjusted EBITDA improved by 81% to $(8,271) thousand from $(42,966) thousand in the previous year[2] - Revenue for the year ended December 31, 2025, increased to $386.2 million, up 52.2% from $253.5 million in 2024[25] - Gross profit for 2025 was $75.5 million, representing a gross margin of 19.5%, compared to $32.4 million in 2024[25] - Net loss for 2025 was $84.5 million, a reduction of 14.5% compared to a net loss of $98.9 million in 2024[25] - The company reported a basic and diluted net loss per common share of $0.89 for 2025, an improvement from $1.04 in 2024[25] - Revenue for the quarter ended December 31, 2025, was $105,349 thousand, representing a 38% increase compared to $76,606 thousand in 2024[35] - Adjusted EBITDA for the quarter ended December 31, 2025, was $(1,407) thousand, a significant improvement from $(4,000) thousand in the same quarter of 2024, reflecting a 65% reduction in losses[38] - The gross profit for the quarter ended December 31, 2025, was $21,066 thousand, a 35% increase from $15,656 thousand in 2024[35] Liquidity and Assets - As of December 31, 2025, total liquidity stood at $312.6 million, which increased to $895.4 million after the IPO on January 30, 2026[7] - Total assets increased to $1.475 billion in 2025, up from $1.320 billion in 2024, reflecting a growth of 11.7%[26] - Cash and cash equivalents were $162.6 million in 2025, up from $104.6 million in 2024, reflecting a growth of 55.5%[26] Operating Expenses and Liabilities - Operating expenses rose to $146.1 million in 2025, an increase of 17.5% from $124.4 million in 2024[25] - Current liabilities decreased to $191.4 million in 2025, down from $225.5 million in 2024, a reduction of 15.1%[26] - The company incurred interest expense of $26,619 thousand for the year ended December 31, 2025, down from $29,923 thousand in 2024[32] - The depreciation and amortization expense for the year ended December 31, 2025, was $50,340 thousand, compared to $48,072 thousand in 2024[32] Growth and Market Expansion - York expects revenue for the full year 2026 to be in the range of $545 million to $595 million, with over 70% expected to come from existing backlog[8] - York finalized a $187 million commercial contract for a 20+ satellite constellation built on the M-CLASS platform, indicating growth in the commercial market[9] - The company has plans for market expansion and new product development, focusing on enhancing user engagement and technology innovation[27] Strategic Initiatives - York delivered 21 Tranche 1 Transport Layer satellites to orbit, becoming the first prime to execute an on-orbit delivery under the Tranche 1 contract[5] - The company launched the Dragoon mission in seven months, a 75% reduction in delivery timeline compared to typical 30-month programs[9] - York acquired ATLAS Space Operations and Orbion Space Technology to enhance its capabilities and supply chain, integrating mission-critical space-to-ground connectivity[9] Inventory and Receivables Management - The company’s accounts receivable net increased by $(8,149,000) in 2025, compared to a minimal change of $(23,000) in 2024, suggesting potential challenges in collections[28] - The company’s inventories increased by $9,751,000 in 2025, contrasting with a decrease of $(11,461,000) in 2024, indicating a shift in inventory management strategy[28] Financial Restructuring - The company raised $235,700,000 from the issuance of Class P Units in 2025, indicating strong financing activity[29] - The company reported a loss on debt extinguishment of $2,201,000 in 2025, reflecting ongoing financial restructuring efforts[28] - Deferred taxes decreased significantly to $(9,632,000) in 2025 from $(18,376,000) in 2024, indicating improved tax management[28]

Store Operations - Burlington Stores operates 1,212 stores as of January 31, 2026, with a long-term target of 2,000 stores[19] - The company opened 113 new stores in Fiscal 2025, compared to 116 in Fiscal 2024 and 91 in Fiscal 2023[20] - Total gross square footage of all stores increased to 52.8 million square feet in Fiscal 2025 from 51.8 million in Fiscal 2024[20] - The distribution centers occupy an aggregate of 5,135,000 square feet, with six centers shipping over 99% of merchandise units[21] Product Categories - Burlington's sales by major product category in Fiscal 2025 included 20% ladies apparel, 28% accessories and shoes, and 20% home[31] - The company has diversified its product offerings, but store traffic is still influenced by weather patterns[44] Customer Demographics - The core customer demographic is aged 25-49, ethnically diverse, with an annual household income of $25,000-$100,000[41] Workforce - The company employs 83,309 associates, with 79% being part-time or seasonal[35] - Burlington has a commitment to increase hourly associates' wages annually since 2010, ensuring competitive compensation[40] Marketing Strategy - Burlington's marketing strategy includes a mix of television, radio, digital, and social media to engage customers effectively[42] Market Competition - The company operates in a highly fragmented and competitive U.S. retail apparel and home furnishings market, competing on price, quality, and customer service[43] Seasonal Influences - The business is subject to seasonal influences, with higher sales and net income typically realized in the second half of the year during back-to-school and holiday seasons[44] Financial Management - As of January 31, 2026, the company had $1,730.6 million of floating-rate debt, with a potential cash interest expense increase or decrease of $6.3 million per year for a one percentage point change in interest rates[275] - On September 24, 2024, the company refinanced $933 million of term B-6 loans into term B-7 loans totaling $1,250 million, extending the maturity date to September 24, 2031, and reducing interest rate margins[269] - The company entered into a new interest rate swap agreement on September 27, 2024, with a notional amount of $500 million at a blended interest rate of 2.83%[272] - The company has unlimited interest rate risk related to borrowings on variable rate debt exceeding the notional principal amount of its interest rate swap contracts[274] - The company manages interest rate risk through interest rate derivative contracts, impacting earnings and cash flows[271] Communication and Trademarks - The company utilizes various channels, including SEC filings and social media, to communicate material information to investors[48] - The company considers its trademarks, including "Burlington" and "Burlington Coat Factory," to be valuable assets that are adequately protected[45]

Global Reach and Customer Base - As of January 31, 2026, the company had customers using its Singularity Platform in approximately 100 countries, indicating a broad global reach[74]. Financial Performance and Trends - The company experienced seasonal fluctuations in financial results, with a higher percentage of annual orders typically received in the fourth fiscal quarter due to customer budget approvals[75]. - As of January 31, 2026, the company had $769.6 million in cash, cash equivalents, and investments, with an additional $26.5 million in restricted cash[407]. - A hypothetical 100 basis point change in interest rates would result in a $3.3 million change in the fair market value of the company's investment portfolio[407]. - The effectiveness of the company's risk management strategy may be limited, potentially affecting financial condition and operating results[409]. Employee Relations and Workplace Culture - The company employed over 2,900 full-time employees worldwide as of January 31, 2026, with a focus on maintaining strong employee relations and no labor union representation[76][80]. - The company has received multiple workplace accolades in 2025, including recognition as a Fortune Future 50 company and Best Workplace in Technology[87]. - The company focuses on employee well-being and has enhanced programs to support physical and mental health, adapting to remote and in-office work environments[88]. Research and Development - The company has made significant investments in research and development, with a focus on core technology innovation and new product delivery, primarily from its offices in Israel, India, and the Czech Republic[89][90]. - As of January 31, 2026, the company held 78 issued patents and 10 pending patent applications, with patents set to expire between 2034 and 2045[103]. Partnerships and Ecosystem - The company has a diverse partner ecosystem, leveraging alliances with leading ISVs, MSPs, and other technology providers to enhance its go-to-market strategies[94][95]. - The Singularity Marketplace allows customers to integrate various applications seamlessly, enhancing visibility and operational efficiency without complex configurations[98][99]. Market and Competitive Landscape - The competitive landscape includes established players like CrowdStrike and Microsoft, with the company emphasizing its autonomous and AI-powered threat prevention capabilities[100][101]. Currency and Investment Management - The company has entered into foreign currency forward contracts with notional amounts of $154.4 million to manage foreign currency exchange rate risk[409]. - All sales contracts to date have been denominated in U.S. dollars, minimizing exposure to foreign currency risk[408]. - Operating expenses incurred outside the U.S. are primarily denominated in local currencies, exposing the company to fluctuations in foreign currency exchange rates[408]. - The company does not enter into investments for trading or speculative purposes, focusing instead on working capital needs[407]. - Foreign currency transaction gains and losses are recorded in other income (expense), net in the consolidated statements of operations[408]. - The company maintains a diverse portfolio of investments, including money market funds, U.S. treasury securities, and corporate notes and bonds[407]. - The company is subject to market risk due to fluctuations in interest rates and foreign currency exchange rates[406].